Cizzle Biotechnology Achieves Significant Fundraising Milestone

We’re excited to share that Cizzle Biotechnology has successfully raised £0.62 million through the issuance of new shares, marking a significant step in advancing medical innovations. This fundraising will accelerate the development and commercialization of the CIZ1B biomarker test, crucial for early-stage lung cancer detection.

Key Achievements:

  • Financial Boost: Raised £0.62 million to propel forward the CIZ1B project.
  • Strategic Partnership: Appointment of Allenby Capital as joint broker to enhance financial strategies.

For more details on this strategic development, visit: Cizzle Bio, Inc.

Tell us how you want to grow.
Let’s get acquainted.


    Give us a call.
    Send us an email.
    Connect with us.